The Institute of Diabetes and Regeneration Research at Helmholtz Zentrum München and Eli Lilly and Company (Lilly) have partnered with the goal of improving and accelerating the treatment of diabetes mellitus. Diabetes mellitus’s long-term complications and co-morbidities represent one of the most devastating and urgent threats to society. While significant progress has been made in...
FDA Approves First Ready-to-Use Stable Liquid Glucagon for Severe Hypoglycemia
The U.S. Food and Drug Administration (FDA) recently approved a ready-to-use, room-temperature stable liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above. Xeris Pharmaceuticals is marketing this new glucagon injection as GVOKE. GVOKE is the first glucagon product approved that can be administered via...
The U.S. Food and Drug Administration last month approved semaglutide oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise. This is the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the United States that does not need to be injected. GLP-1...
In the House: How Inpatient Diabetes Teams Can Improve Patient Outcomes and Reduce Costs
Becoming more common in academic institutions, diabetes management teams can play an important role in community hospitals by reducing lengths of stay and readmissions. Evidence continues to mount that focusing on patients’ diabetes through inpatient management services when they are in the hospital for other conditions pays dividends in lowering re-admissions and short-term mortality —...
Hormone Health Network Launches Severe Hypoglycemia Awareness Campaign
People with diabetes and their friends and relatives will be better prepared to spot the signs of dangerously low blood sugar using new resources the Hormone Health Network has introduced. The Hormone Health Network, the Endocrine Society’s public education arm, created the KNOW HYPO public awareness campaign to help people identify when a person has...FDA Approves First Treatment for Severe Hypoglycemia That Can Be Administered without an Injection
In July, the U.S. Food and Drug Administration approved a nasal powder glucagon therapy for the emergency treatment of severe hypoglycemia that can be administered without an injection. Eli Lilly and Company is marketing the drug as Baqsimi. The therapy has been approved to treat severe hypoglycemia in patients with diabetes ages four and older....Slumber Party: How Acute Sleep Loss Affects the Endocrine System
There is an increasing amount of research on how a lack of sleep impacts endocrine system from increasing obesity to contributing to diabetes. Jonathan Cedernaes, PhD, discusses his research on this subject and what it means for the sleepless patients as well as the clinicians who treat them. Three years ago, Endocrine News ran a...
Endocrine News talks with James Rosenzweig, MD, chair of the task force that developed the latest Endocrine Society Clinical Practice Guideline on Preventing Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk. A new Endocrine Society clinical practice guideline states that measuring waistline, blood pressure, cholesterol, and blood sugar during doctor’s visits could...
